Shannon Heaning, Content Associate

Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.

October brought FDA approvals in urticaria and HSV, new regulatory filings, and phase 3 advances in HS, psoriasis, and rare diseases.

A case highlights how pet ownership may support mental health, activity, routine, and quality of life in a patient living with hidradenitis suppurativa.

New HS treatment guidelines emphasize expanded biologic options, individualized care, and early intervention to prevent irreversible damage.

A 2026 study links Agent Orange exposure to higher odds of acral melanoma in US veterans, highlighting the importance of early detection.

Phase 2 BEACON findings published in JAMA Dermatology demonstrate rapid improvements in disease activity and skin-related quality of life with oral brepocitinib.

Phase 2 AMETHYST findings show continued improvements in skin redness and clinician- and patient-reported outcomes with litifilimab.

Phase 2/3 data show sustained hair growth and favorable safety outcomes with oral VDPHL01 in men with androgenetic alopecia.

BE BOLD Week 24 data show sustained numerical advantages in joint responses with bimekizumab versus risankizumab in active psoriatic arthritis.

National NP Week 2026 highlights how nurse practitioners are expanding access to care, advancing clinical practice, and leading health care innovation.

The AADA warns that dermatologists could face a 6% Medicare payment reduction in 2027 despite CMS revisions to modifier 25 policies.

Stay ahead with a weekly roundup of the biggest practice management, AI, policy, business, and professional development updates in dermatology.

Diego Ruiz Dasilva, MD, and Lindsey Finklea, MD, discuss the burden of chronic inducible urticaria and phase 3 remIND findings for remibrutinib.

Doral Fredericks, PharmD, MBA, discusses how life stages, mental health, and reproductive concerns can shape dermatologic care for women.

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

Dermatology Times is looking back on the top stories in dermatology from the month of October.

From “Botox in a bottle” to castor oil and face taping, Dermatology Times reviews the evidence behind 3 viral dermatology trends from October.

Dermatology PAs unpack 4 frightening skin care myths and trends, from sunscreen misinformation and citrus DIYs to overusing actives and beef tallow.

Dermatology Times recaps Eczema Awareness Month with expert insights on disease burden, individualized treatment, systemic therapies, and gaps in care access.

The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.

Elevate-Derm Summer 2026 faculty share practical lessons on hair loss exams, PIH, geriatric dermatology, and managing cholesterol rises on JAK inhibitors.

A melanoma expert discusses gaps in dermoscopy education, cognitive bias during skin examinations, and strategies to improve early melanoma detection.

Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.

ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.

Feldman challenges common eczema myths and highlights the disease’s effects on sleep, mental health, treatment adherence, and quality of life.

LRM will evaluate injectable rhPDGF-BB as a regenerative approach to infraorbital hollowing in a randomized phase 2b trial.

ORKA-001 achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B trial of moderate-to-severe psoriasis.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Stratman discusses individualized eczema care, expanding treatment options, and the potential of precision medicine to guide therapy.